Cover Image

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Yi Zhao, Yi Li, Wenjun Wu, Zhen Cai
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Cancer Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
by: Danai Dima, et al.
Published: (2024)

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study
by: Olivier Decaux, et al.
Published: (2024)

Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
by: Deniz Gezer, et al.
Published: (2024)

Teclistamab for relapsed refractory multiple myeloma patients on dialysis
by: P. Lebreton, et al.
Published: (2024)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025)

Retreatment with talquetamab and pomalidomide in triple‐class– BCMA – GPRC5D refractory myeloma
by: Kian J. Rahbari, et al.
Published: (2026)

Mechanisms of resistance to daratumumab in patients with multiple myeloma
by: Katrine Fladeland Iversen
Published: (2024)

Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study
by: Cyrille Hulin, et al.
Published: (2024)

Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series
by: Gráinne Marron, et al.
Published: (2026)

Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
by: Jing An, et al.
Published: (2024)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
by: Danilo De Novellis, et al.
Published: (2024)

CAR T‐cell therapy shows impressive outcomes for patients with refractory multiple myeloma
by: Mary Beth Nierengarten
Published: (2025)

Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort
by: Thomas G. Martin, et al.
Published: (2026)

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
by: M. R. Seefat, et al.
Published: (2025)

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
by: Syed Naqvi, et al.
Published: (2024)

Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma
by: Xi‐xi Yin, et al.
Published: (2024)

The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
by: Yutaka Shimazu, et al.
Published: (2024)

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
by: Taku Kikuchi, et al.
Published: (2024)

Resumption of bone‐modifying agents in relapsed multiple myeloma does not improve outcomes: A real‐world analysis
by: Malcolm Su, et al.
Published: (2026)

Real‐world experience with CAR‐T therapy in relapsed and refractory follicular lymphoma
by: Nicolás Triantafilo, et al.
Published: (2025)

Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”
Published: (2026)

Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis
by: Abdul‐Hamid Bazarbachi, et al.
Published: (2024)

Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma
by: Luca Bettolini, et al.
Published: (2024)

T‐cell‐based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic
by: S. Moraru, et al.
Published: (2025)

A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
by: Eric Wenlong Li, et al.
Published: (2024)

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
by: Anna Furlan, et al.
Published: (2024)

Real‐world outcomes of patients with relapsed/refractory large B‐cell lymphoma receiving second‐line therapy in England
by: Christopher P. Fox, et al.
Published: (2024)

“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
by: Kevin C. Graf, et al.
Published: (2024)

Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial
by: Maria‐Victoria Mateos, et al.
Published: (2024)

Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma
by: Carolina Perrone Marques, et al.
Published: (2024)

Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
by: Roxanne C. Jewell, et al.
Published: (2024)

Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
by: Dian Jin, et al.
Published: (2024)

Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime
by: Joshua Bomsztyk, et al.
Published: (2024)

Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study
by: Danai Dima, et al.
Published: (2024)

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
by: Michael H. Tomasson, et al.
Published: (2024)

An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
by: Prashant Kapoor, et al.
Published: (2024)

Reversing the sequence: Efficacy of BCMA‐directed therapy following progression on GPRC5D ‐directed therapies in relapsed multiple myeloma
by: Laura Joiner, et al.
Published: (2025)

High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
by: Andrea Manubens, et al.
Published: (2025)

The role of proliferating stem‐like plasma cells in relapsed or refractory multiple myeloma: Insights from single‐cell RNA sequencing and proteomic analysis
by: Jiadai Xu, et al.
Published: (2024)

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
by: Cyrille Touzeau, et al.
Published: (2025)